Drugs / QLC7401
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07074236 | Jul 2025 → Jan 2026 overdue | hyperlipidemia | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06750341 | Feb 2025 → Jun 2026 overdue | hyperlipoproteinemia | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07450378 | May 2026 → Apr 2028 expected | familial hypercholesterolemia | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07444086 | Mar 2026 → Oct 2027 expected | hyperlipoproteinemia | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07441317 | Mar 2026 → Dec 2027 expected | hyperlipoproteinemia | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLC7401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06750341 ↗ |
| Modality | Small interfering RNA (siRNA) | “small interfering RNA (siRNA)” NCT07450378 ↗ |
| Route | Subcutaneous | “QLC7401 subcutaneous administration” NCT06750341 ↗ |
| Target | PCSK9 | “targeting PCSK9” NCT07450378 ↗ |